Francesco Moroni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesco Moroni has a total of 476 co-authors. Here are the top co-authors by number of shared publications:
- Enrico Ammirati
De Gasperis Cardio Center, Transplant Center, Niguarda Hospital, Milano, Italy (E.A.).
22 shared publications Marco Magnoni
Vita-Salute University and San Raffaele Hospital, Milan, Italy
12 shared publications- Antonio Abbate
University of Virginia
11 shared publications - Lorenzo Azzalini
Department of Medicine, Division of Cardiology University of Washington Seattle Washington USA
10 shared publications Isabella Scotti
Department of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy
9 shared publications- Paolo Guido Camici
Vita Salute University and San Raffaele Hospital, Milan, Italy
9 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Elsevier in Journal of Cardiac Failure - Intersections
Systemic Inflammation and Cardiorespiratory Fitness in Heart Failure: A Pooled Analysis of Anakinra Clinical Trials
- 7 October 2026
- Published by Elsevier in Journal of Cardiac Failure - Intersections
Open AccessSystemic Inflammation and Cardiorespiratory Fitness in Heart Failure: A Pooled Analysis of Anakinra Clinical Trials
- 9 May 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (9) , 103107
Real-World Analysis of Malnutrition and 1-Year Mortality in Patients Treated With Temporary Mechanical Circulatory Support
- 9 May 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (9) , 103107
Real-World Analysis of Malnutrition and 1-Year Mortality in Patients Treated With Temporary Mechanical Circulatory Support
- Top Cited Papers
- 3 March 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (9) , 634-652
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis
BACKGROUND: No large registries of patients with acute eosinophilic myocarditis (EM) are available. However, EM is perceived as a cardiac disease with high mortality, affecting mainly young and middle-aged adults according to small series and case reports. Awareness of the clinical presentation, associated systemic conditions, treatments, and outcomes of this uncommon condition is an unmet need. METHODS: In this international, multicenter, retrospective cohort study, 53 centers screened 193 patients with histologically proven acute EM between 1992 and 2023. After the exclusion of patients with insufficient data (n=10), symptoms lasting >30 days (n=19), or histological diagnosis not confirmed after review (n=8), 156 patients were included. RESULTS: Median age at presentation was 48 years (first to third quartile, 34–59 years) with male predominance (67.3%), and only 2 were pediatric cases (≤16 years of age; 1.3%). The main signs and symptoms at presentation were dyspnea (75.6%), fever (61.3%), and chest pain (53.2%). Unexpectedly, peripheral eosinophilia was reported in only 57.4% of cases, with a median cell count of 630 eosinophils/μL. The median left ventricular ejection fraction at presentation was 32% (first to third quartile, 25%–48%). The disorders most frequently associated with EM were eosinophilic granulomatosis with polyangiitis (22.4% of cases) and hypersensitivity forms (14.1%). Idiopathic/undefined forms accounted for 44.9% of cases, and miscellaneous causes accounted for 18.6%. In-hospital death or need for heart transplantation (HTx) occurred in 23 patients (14.7%; 22 deaths and 1 HTx), despite 43.6% being treated with temporary mechanical circulatory support and 92.9% being treated with immunosuppressive agents. Estimated rates of death or HTx at 1 and 3 years were 19.0% and 23.8%. Increased age, decreased left ventricular ejection fraction on admission, and no immunosuppressive therapy during hospitalization were independent predictors of death or HTx. A nonsignificant higher occurrence of deaths or HTx was observed in the hypersensitivity form (46.1%) compared with the eosinophilic granulomatosis with polyangiitis–associated form (13.1%) at 3 years ( P =0.15). CONCLUSIONS: Acute EM can often present without peripheral eosinophilia, and rates of in-hospital and midterm mortality or HTx are high. Endomyocardial biopsy is required to reach the final diagnosis of EM because relying on peripheral eosinophilia can lead to missing diagnosis. In-hospital immunosuppression is associated with HTx-free survival, although tailored immunosuppressive therapies are needed to improve outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06447935.
- 3 March 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (9) , 634-652
Top Cited PapersNatural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis
BACKGROUND: No large registries of patients with acute eosinophilic myocarditis (EM) are available. However, EM is perceived as a cardiac disease with high mortality, affecting mainly young and middle-aged adults according to small series and case reports. Awareness of the clinical presentation, associated systemic conditions, treatments, and outcomes of this uncommon condition is an unmet need. METHODS: In this international, multicenter, retrospective cohort study, 53 centers screened 193 patients with histologically proven acute EM between 1992 and 2023. After the exclusion of patients with insufficient data (n=10), symptoms lasting >30 days (n=19), or histological diagnosis not confirmed after review (n=8), 156 patients were included. RESULTS: Median age at presentation was 48 years (first to third quartile, 34–59 years) with male predominance (67.3%), and only 2 were pediatric cases (≤16 years of age; 1.3%). The main signs and symptoms at presentation were dyspnea (75.6%), fever (61.3%), and chest pain (53.2%). Unexpectedly, peripheral eosinophilia was reported in only 57.4% of cases, with a median cell count of 630 eosinophils/μL. The median left ventricular ejection fraction at presentation was 32% (first to third quartile, 25%–48%). The disorders most frequently associated with EM were eosinophilic granulomatosis with polyangiitis (22.4% of cases) and hypersensitivity forms (14.1%). Idiopathic/undefined forms accounted for 44.9% of cases, and miscellaneous causes accounted for 18.6%. In-hospital death or need for heart transplantation (HTx) occurred in 23 patients (14.7%; 22 deaths and 1 HTx), despite 43.6% being treated with temporary mechanical circulatory support and 92.9% being treated with immunosuppressive agents. Estimated rates of death or HTx at 1 and 3 years were 19.0% and 23.8%. Increased age, decreased left ventricular ejection fraction on admission, and no immunosuppressive therapy during hospitalization were independent predictors of death or HTx. A nonsignificant higher occurrence of deaths or HTx was observed in the hypersensitivity form (46.1%) compared with the eosinophilic granulomatosis with polyangiitis–associated form (13.1%) at 3 years ( P =0.15). CONCLUSIONS: Acute EM can often present without peripheral eosinophilia, and rates of in-hospital and midterm mortality or HTx are high. Endomyocardial biopsy is required to reach the final diagnosis of EM because relying on peripheral eosinophilia can lead to missing diagnosis. In-hospital immunosuppression is associated with HTx-free survival, although tailored immunosuppressive therapies are needed to improve outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06447935.
- Top Cited Papers
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (3) , e013546
Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra
BACKGROUND: Decompensated heart failure with reduced ejection fraction (HFrEF) is associated with systemic inflammation that predicts unfavorable outcomes. We aimed to determine whether anakinra, an IL-1 (interleukin-1) blocker, favors inflammation resolution (CRP [C-reactive protein]) and improves peak oxygen consumption (VO 2 ) in patients with recently decompensated HFrEF. METHODS: We randomized 102 adult patients recently hospitalized for HFrEF and CRP ≥2 mg/L (2:1) to receive anakinra 100 mg subcutaneously daily (n=68) or placebo for 24 weeks (n=34). The primary end point was the peak VO 2 change at 24 weeks. Data are presented as median (Q1, Q3) or number (%). RESULTS: Of the 102 patients, 84 had primary end point data available (57 treated with anakinra and 27 with placebo). Peak VO 2 increased from 13.0 (10.9, 17.0) to 14.9 (12.0, 18.0) mL·kg⁻ 1 ·min⁻ 1 ( P 1 ·min⁻ 1 , respectively; P =0.40; median difference +0.30 mL·kg⁻ 1 ·min⁻ 1 [95% CI from −1.70 to +0.90]). A significant reduction in CRP levels was seen, with a −76% (−87%, −36%) in anakinra-treated patients and −48% (−77%, +14%) in the placebo group ( P =0.050 between groups). There were no unexpected treatment-related serious adverse events, and no differences in HFrEF events between groups. CRPP =0.48). Patients achieving CRP2 versus those with CRP≥2 mg/L (+2.6 [+0.7, +4.6] and +1.0 [−0.3, +1.9] mL·kg⁻ 1 ·min⁻ 1 ; P =0.007) and lower rates of HFrEF-related events (8% and 26%; P =0.045). CONCLUSIONS: Patients with recently decompensated HFrEF treated with maximally tolerated medical therapy had a significant improvement in CRP and peak VO 2 . The addition of anakinra had a modest effect on CRP levels and no significant effect on peak VO 2 or other clinically relevant secondary end points. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03797001.
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (3) , e013546
Top Cited PapersResolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra
BACKGROUND: Decompensated heart failure with reduced ejection fraction (HFrEF) is associated with systemic inflammation that predicts unfavorable outcomes. We aimed to determine whether anakinra, an IL-1 (interleukin-1) blocker, favors inflammation resolution (CRP [C-reactive protein]) and improves peak oxygen consumption (VO 2 ) in patients with recently decompensated HFrEF. METHODS: We randomized 102 adult patients recently hospitalized for HFrEF and CRP ≥2 mg/L (2:1) to receive anakinra 100 mg subcutaneously daily (n=68) or placebo for 24 weeks (n=34). The primary end point was the peak VO 2 change at 24 weeks. Data are presented as median (Q1, Q3) or number (%). RESULTS: Of the 102 patients, 84 had primary end point data available (57 treated with anakinra and 27 with placebo). Peak VO 2 increased from 13.0 (10.9, 17.0) to 14.9 (12.0, 18.0) mL·kg⁻ 1 ·min⁻ 1 ( P 1 ·min⁻ 1 , respectively; P =0.40; median difference +0.30 mL·kg⁻ 1 ·min⁻ 1 [95% CI from −1.70 to +0.90]). A significant reduction in CRP levels was seen, with a −76% (−87%, −36%) in anakinra-treated patients and −48% (−77%, +14%) in the placebo group ( P =0.050 between groups). There were no unexpected treatment-related serious adverse events, and no differences in HFrEF events between groups. CRPP =0.48). Patients achieving CRP2 versus those with CRP≥2 mg/L (+2.6 [+0.7, +4.6] and +1.0 [−0.3, +1.9] mL·kg⁻ 1 ·min⁻ 1 ; P =0.007) and lower rates of HFrEF-related events (8% and 26%; P =0.045). CONCLUSIONS: Patients with recently decompensated HFrEF treated with maximally tolerated medical therapy had a significant improvement in CRP and peak VO 2 . The addition of anakinra had a modest effect on CRP levels and no significant effect on peak VO 2 or other clinically relevant secondary end points. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03797001.
- Top Cited PapersOpen Access
- 12 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Residual inflammatory risk and clinical outcomes after contemporary percutaneous coronary intervention: a systematic review and meta-analysis
Elevated low-density lipoprotein cholesterol (LDL-C) and subclinical inflammation - measured with high-sensitivity C-reactive protein (hsCRP) - contribute to atherosclerosis progression. Despite medical therapy, high-risk patients may still have residual cholesterol risk, residual inflammatory risk (RIR), both, or neither. We aimed to study the impact of RIR in patients undergoing contemporary percutaneous coronary intervention (PCI). A comprehensive search of Pubmed, EMBASE, Cochrane and MEDLINE was performed up to December 2024. Only studies including patients with coronary artery disease undergoing PCI were considered. Inflammatory burden was evaluated with two hs-CRP measurements at baseline and follow-up (> 4 weeks apart). High RIR was defined as hsCRP ≥ 2 mg/L at 1-month follow-up. The risk ratio (RR) with a 95% confidence interval (CI) was computed using a random-effect model. We identified five studies enrolling 13,604 patients, including 5,833 with high RIR at 30 days post–PCI. At 12-month follow-up, persistent high RIR was associated with an increased risk of major adverse cardiovascular events (MACE) (random-effects RR = 1.64, 95% CI 1.33–2.03; I² = 80.2%). High RIR was also associated with increased all-cause mortality (random-effects RR = 3.25, 95% CI 2.49–4.25; I² = 67%), non-fatal myocardial infarction (random-effects RR = 1.46, 95% CI 1.00–2.12; I² = 73%), and non-fatal stroke (random-effects RR = 1.64, 95% CI 1.14–2.37; I² = 0%). Sensitivity analyses, including Baujat plots and leave-one-out analyses, identified a single study as a major contributor to heterogeneity; exclusion of this study substantially reduced heterogeneity without materially altering the direction or magnitude of the associations. In patients undergoing contemporary PCI, a high RIR was associated with a significantly higher risk of adverse cardiovascular outcomes. This data could help tailor lipid-lowering and anti-inflammatory therapies in this high-risk population.
- 12 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Top Cited PapersOpen AccessResidual inflammatory risk and clinical outcomes after contemporary percutaneous coronary intervention: a systematic review and meta-analysis
Elevated low-density lipoprotein cholesterol (LDL-C) and subclinical inflammation - measured with high-sensitivity C-reactive protein (hsCRP) - contribute to atherosclerosis progression. Despite medical therapy, high-risk patients may still have residual cholesterol risk, residual inflammatory risk (RIR), both, or neither. We aimed to study the impact of RIR in patients undergoing contemporary percutaneous coronary intervention (PCI). A comprehensive search of Pubmed, EMBASE, Cochrane and MEDLINE was performed up to December 2024. Only studies including patients with coronary artery disease undergoing PCI were considered. Inflammatory burden was evaluated with two hs-CRP measurements at baseline and follow-up (> 4 weeks apart). High RIR was defined as hsCRP ≥ 2 mg/L at 1-month follow-up. The risk ratio (RR) with a 95% confidence interval (CI) was computed using a random-effect model. We identified five studies enrolling 13,604 patients, including 5,833 with high RIR at 30 days post–PCI. At 12-month follow-up, persistent high RIR was associated with an increased risk of major adverse cardiovascular events (MACE) (random-effects RR = 1.64, 95% CI 1.33–2.03; I² = 80.2%). High RIR was also associated with increased all-cause mortality (random-effects RR = 3.25, 95% CI 2.49–4.25; I² = 67%), non-fatal myocardial infarction (random-effects RR = 1.46, 95% CI 1.00–2.12; I² = 73%), and non-fatal stroke (random-effects RR = 1.64, 95% CI 1.14–2.37; I² = 0%). Sensitivity analyses, including Baujat plots and leave-one-out analyses, identified a single study as a major contributor to heterogeneity; exclusion of this study substantially reduced heterogeneity without materially altering the direction or magnitude of the associations. In patients undergoing contemporary PCI, a high RIR was associated with a significantly higher risk of adverse cardiovascular outcomes. This data could help tailor lipid-lowering and anti-inflammatory therapies in this high-risk population.
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (10) , e015387
Comparative Effectiveness of TAVI Platforms and Surgical Aortic Valve Replacement: A Network Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR). METHODS: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR. The certainty of the evidence was assessed following the Grading of Recommendations, Assessment, Development, and Evaluations approach. We performed a frequentist network meta-analysis to generate treatment effect estimates. All-cause, cardiovascular mortality, and stroke were considered critically important patient-centered outcomes. RESULTS: We identified 11 randomized controlled trials with 9946 participants and reporting outcomes between 1 to 10 years. TAVI with CoreValve-Evolut was associated with a similar risk of all-cause (absolute risk difference [ARD], 31/1000 from −12 to 79), and cardiovascular mortality (ARD, −8/1000 from −39 to 28) compared with SAVR (moderate certainty). Compared with SAVR, TAVI with SAPIEN and ACURATE neo were associated with an increased risk of all-cause (ARD, 109/1000 from 56 to 169, high certainty and ARD, 123/1000 from 9 to 277, moderate certainty, respectively) and cardiovascular mortality (ARD, 58/1000 from 18 to 105, high certainty and ARD, 105 from 7 to 247, moderate certainty, respectively). Moderate and high-certainty evidence showed that all TAVI platforms were associated with an increased risk of reinterventions and pacemaker implant versus SAVR. Compared with TAVI with CoreValve-Evolut, SAPIEN was associated with higher all-cause (ARD, 75/1000 from 13 to 147, high certainty) and cardiovascular mortality (ARD, 66/1000 from 15 to 130, high certainty), same scenario for ACURATE neo (ARD 113/1000 from 13 to 259, high certainty). CONCLUSIONS: TAVI with CoreValve-Evolut is probably associated with similar mortality to SAVR. TAVI with SAPIEN and ACURATE neo were associated with increased risk of mortality compared with SAVR and CoreValve-Evolut. The current body of evidence from randomized controlled trials goes against the hypothesis of a class effect across TAVI valves. REGISTRATION: URL: https://www.crd.york.ac.uk ; Unique identifier: CRD42024512026.
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (10) , e015387
Comparative Effectiveness of TAVI Platforms and Surgical Aortic Valve Replacement: A Network Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR). METHODS: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR. The certainty of the evidence was assessed following the Grading of Recommendations, Assessment, Development, and Evaluations approach. We performed a frequentist network meta-analysis to generate treatment effect estimates. All-cause, cardiovascular mortality, and stroke were considered critically important patient-centered outcomes. RESULTS: We identified 11 randomized controlled trials with 9946 participants and reporting outcomes between 1 to 10 years. TAVI with CoreValve-Evolut was associated with a similar risk of all-cause (absolute risk difference [ARD], 31/1000 from −12 to 79), and cardiovascular mortality (ARD, −8/1000 from −39 to 28) compared with SAVR (moderate certainty). Compared with SAVR, TAVI with SAPIEN and ACURATE neo were associated with an increased risk of all-cause (ARD, 109/1000 from 56 to 169, high certainty and ARD, 123/1000 from 9 to 277, moderate certainty, respectively) and cardiovascular mortality (ARD, 58/1000 from 18 to 105, high certainty and ARD, 105 from 7 to 247, moderate certainty, respectively). Moderate and high-certainty evidence showed that all TAVI platforms were associated with an increased risk of reinterventions and pacemaker implant versus SAVR. Compared with TAVI with CoreValve-Evolut, SAPIEN was associated with higher all-cause (ARD, 75/1000 from 13 to 147, high certainty) and cardiovascular mortality (ARD, 66/1000 from 15 to 130, high certainty), same scenario for ACURATE neo (ARD 113/1000 from 13 to 259, high certainty). CONCLUSIONS: TAVI with CoreValve-Evolut is probably associated with similar mortality to SAVR. TAVI with SAPIEN and ACURATE neo were associated with increased risk of mortality compared with SAVR and CoreValve-Evolut. The current body of evidence from randomized controlled trials goes against the hypothesis of a class effect across TAVI valves. REGISTRATION: URL: https://www.crd.york.ac.uk ; Unique identifier: CRD42024512026.
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (6) , e014940
Effect of TAVI on Epicardial Functional Indices and Their Relationship to Coronary Microvascular Function
BACKGROUND: The anatomic and physiological changes associated with severe aortic stenosis may influence the functional evaluation of coronary stenoses. In this study, we aimed to assess changes in functional resting and hyperemic indices before and immediately after transcatheter aortic valve implantation (TAVI) and their relationship with microvascular resistance. METHODS: In this pooled analysis of 3 prospective observational studies, fractional flow reserve (FFR), resting full-cycle ratio (RFR), and resting distal coronary pressure to aortic pressure ratio (Pd/Pa) were measured in patients with severe aortic stenosis before and after TAVI in the left anterior descending artery. Coronary microcirculation was also assessed using thermodilution-based methods, with microvascular resistance reserve (cutoff ≤3) used to identify coronary microvascular dysfunction. RESULTS: A total of 126 patients were included. Baseline Pd/Pa, RFR, and FFR measurements were 0.93±0.04, 0.90±0.07, and 0.89±0.07, respectively. Immediately post-TAVI, a small but significant decrease was observed for both RFR and FFR (RFR, 0.88±0.08; FFR, 0.88±0.08; P P P <0.001 for both). The rate of disagreement between resting and hyperemic indices remained unchanged, regardless of the presence of coronary microvascular dysfunction. CONCLUSIONS: TAVI is associated with a small but significant reduction in FFR and RFR immediately post-procedure. Overall, the agreement between pre- and post-TAVI values of FFR was higher compared with resting indices.
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (6) , e014940
Effect of TAVI on Epicardial Functional Indices and Their Relationship to Coronary Microvascular Function
BACKGROUND: The anatomic and physiological changes associated with severe aortic stenosis may influence the functional evaluation of coronary stenoses. In this study, we aimed to assess changes in functional resting and hyperemic indices before and immediately after transcatheter aortic valve implantation (TAVI) and their relationship with microvascular resistance. METHODS: In this pooled analysis of 3 prospective observational studies, fractional flow reserve (FFR), resting full-cycle ratio (RFR), and resting distal coronary pressure to aortic pressure ratio (Pd/Pa) were measured in patients with severe aortic stenosis before and after TAVI in the left anterior descending artery. Coronary microcirculation was also assessed using thermodilution-based methods, with microvascular resistance reserve (cutoff ≤3) used to identify coronary microvascular dysfunction. RESULTS: A total of 126 patients were included. Baseline Pd/Pa, RFR, and FFR measurements were 0.93±0.04, 0.90±0.07, and 0.89±0.07, respectively. Immediately post-TAVI, a small but significant decrease was observed for both RFR and FFR (RFR, 0.88±0.08; FFR, 0.88±0.08; P P P <0.001 for both). The rate of disagreement between resting and hyperemic indices remained unchanged, regardless of the presence of coronary microvascular dysfunction. CONCLUSIONS: TAVI is associated with a small but significant reduction in FFR and RFR immediately post-procedure. Overall, the agreement between pre- and post-TAVI values of FFR was higher compared with resting indices.
- 31 October 2024
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 10 (12) , 2732-2734
QT Prolongation and 1-Year Outcomes in Patients With Takotsubo Syndrome
- 31 October 2024
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 10 (12) , 2732-2734
QT Prolongation and 1-Year Outcomes in Patients With Takotsubo Syndrome
- Open Access
- 20 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (4) , e032143
Cardiac Involvement in Patients With Multisystem Inflammatory Syndrome in Adults
Multisystemic inflammatory syndrome in adults is a hyperinflammatory condition following (within 4-12 weeks) SARS-CoV-2 infection. Here, the dysregulation of the immune system leads to a multiorgan involvement often affecting the heart. Cardiac involvement in multisystemic inflammatory syndrome in adults has been described mainly in young men without other comorbidities and may present with different clinical scenarios, including acute heart failure, life-threatening arrhythmias, pericarditis, and myocarditis, with a nonnegligible risk of mortality (up to 7% of all cases). The heterogeneity of its clinical features and the absence of a clear case definition make the differential diagnosis with other postinfectious (eg, infective myocarditis) and hyperinflammatory diseases (eg, adult Still disease and macrophage activation syndrome) challenging. Moreover, the evidence on the efficacy of specific treatments targeting the hyperinflammatory response underlying this clinical condition (eg, glucocorticoids, immunoglobulins, and other immunomodulatory agents) is sparse and not supported by randomized clinical trials. In this review article, we aim to provide an overview of the clinical features and the diagnostic workup of multisystemic inflammatory syndrome in adults with cardiac involvement, highlighting the possible pathogenetic mechanisms and the therapeutic management, along with remaining knowledge gaps in this field.
- 20 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (4) , e032143
Open AccessCardiac Involvement in Patients With Multisystem Inflammatory Syndrome in Adults
Multisystemic inflammatory syndrome in adults is a hyperinflammatory condition following (within 4-12 weeks) SARS-CoV-2 infection. Here, the dysregulation of the immune system leads to a multiorgan involvement often affecting the heart. Cardiac involvement in multisystemic inflammatory syndrome in adults has been described mainly in young men without other comorbidities and may present with different clinical scenarios, including acute heart failure, life-threatening arrhythmias, pericarditis, and myocarditis, with a nonnegligible risk of mortality (up to 7% of all cases). The heterogeneity of its clinical features and the absence of a clear case definition make the differential diagnosis with other postinfectious (eg, infective myocarditis) and hyperinflammatory diseases (eg, adult Still disease and macrophage activation syndrome) challenging. Moreover, the evidence on the efficacy of specific treatments targeting the hyperinflammatory response underlying this clinical condition (eg, glucocorticoids, immunoglobulins, and other immunomodulatory agents) is sparse and not supported by randomized clinical trials. In this review article, we aim to provide an overview of the clinical features and the diagnostic workup of multisystemic inflammatory syndrome in adults with cardiac involvement, highlighting the possible pathogenetic mechanisms and the therapeutic management, along with remaining knowledge gaps in this field.
- Open Access
- 3 October 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (19) , e031786
Connecting the Dots: Inflammatory Burden and Outcomes in Heart Failure
- 3 October 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (19) , e031786
Open AccessConnecting the Dots: Inflammatory Burden and Outcomes in Heart Failure